S
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Shana M. Owens' research primarily investigates viral infections, with a focus on gammaherpesviruses and SARS-CoV-2. Her work on gammaherpesviruses explores mechanisms of viral latency and reactivation, including the role of B cells and STAT3 signaling in maintaining latency. She has also studied the potential of replication-deficient gammaherpesvirus vaccines in protecting against disease and reducing latency. In parallel, Owens has contributed to understanding the immunological consequences of SARS-CoV-2 infection, specifically examining the development of ACE2 autoantibodies and assessing seroprevalence across different demographics and time points in Arkansas. Her research network includes consistent collaboration with colleagues at the University of Arkansas for Medical Sciences, evidenced by numerous shared publications with J. Craig Forrest, Joshua L. Kennedy, Catherine Kirkpatrick, and Marianne Kouassi. Owens' scholarship includes 25 publications and has garnered 349 citations, with an h-index of 6.
Metrics
- h-index: 6
- Publications: 26
- Citations: 355
Selected Publications
-
The amplitude of gammaherpesvirus lytic replication dictates adaptive immune activation: Potential implications for KSHV LANA in immune evasion (2026)
-
Intrinsic p53 activation restricts gammaherpesvirus driven germinal center B cell expansion during latency establishment (2025)
-
A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment (2024)
-
Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models (2024)
-
Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice (2023)
-
B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model (2023)
-
Lytic Replication and Reactivation from B Cells Is Not Required for Establishing or Maintaining Gammaherpesvirus Latency <i>In Vivo</i> (2022)
-
Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas (2022)
-
Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic (2022)
-
Development of ACE2 autoantibodies after SARS-CoV-2 infection (2021)
-
Lytic Replication and Reactivation from B Cells Is Not Required for Maintaining Gammaherpesvirus Latency <i>in vivo</i> (2021)
-
Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic (2021)
-
Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas (2021)
Collaboration Network
Top Collaborators
J. Craig Forrest
University of Arkansas for Medical Sciences
16 shared publications
In database
- Development of ACE2 autoantibodies after SARS-CoV-2 infection
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
Showing 5 of 16 shared publications
Joshua L. Kennedy
7 shared publications
In database
- Development of ACE2 autoantibodies after SARS-CoV-2 infection
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Correction: Development of ACE2 autoantibodies after SARS-CoV-2 infection
Showing 5 of 7 shared publications
Laura P. James
University of Arkansas for Medical Sciences (US)
5 shared publications
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Catherine Kirkpatrick
Arkansas Children's Hospital
5 shared publications
In database
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Zeel Modi
Arkansas Children's Hospital (US)
5 shared publications
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Katherine Caid
Arkansas Children's Hospital (US)
5 shared publications
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Namvar Zohoori
Arkansas Department of Health (US)
5 shared publications
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Karl W. Boehme
5 shared publications
- Development of ACE2 autoantibodies after SARS-CoV-2 infection
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020
- Correction: Development of ACE2 autoantibodies after SARS-CoV-2 infection
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Chad H. Hogan
5 shared publications
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
Varvara Kirillov
5 shared publications
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
Camille Khairallah
5 shared publications
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
Brian S. Sheridan
5 shared publications
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
Laurie T. Krug
5 shared publications
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
Jessica Snowden
University of Arkansas for Medical Sciences
4 shared publications
In database
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Marianne Kouassi
University of Arkansas for Medical Sciences
4 shared publications
In database
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
Similar Researchers
Based on overlapping research topics
J. Craig Forrest
University of Arkansas for Medical Sciences
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Viral Infections and Vectors
Shane Babcock
National Center for Toxicological Research
SARS-CoV-2 and COVID-19 Research
Viral Infections and Vectors
Public Health Research
Jiao Song
University of Arkansas for Medical Sciences
Herpesvirus Infections and Treatments
SARS-CoV-2 and COVID-19 Research
Viral Infections and Vectors
Akrm Abdalrahman
University of Arkansas for Medical Sciences
Herpesvirus Infections and Treatments
Viral Infections and Vectors
Disease Mechanisms Research
Karina Clemmons
University of Arkansas for Medical Sciences
SARS-CoV-2 and COVID-19 Research
Public Health Research
Disease Mechanisms Research
Steven Murdock
University of Arkansas for Medical Sciences
Herpesvirus Infections and Treatments
Viral Infections and Vectors
Disease Mechanisms Research